IC
BCLI

Ikarian Capital’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Ikarian Capital’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-78,007
Closed -$19.8M – 236
2020
Q3 		$19.8M Buy
+78,007
New +$16M 1.43% 16

Other funds holding BCLI

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LWM
Liberty Wealth Management Oakland, California $800M AUM 20.44% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
WCG
Weaver Consulting Group Huntington Beach, California $488M AUM 17.59% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Ikarian Capital's BCLI Position: Q1 2025 in Review

Ikarian Capital sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q1 2025, closing a stake of 6,016 shares — an estimated $13.7K sold.

Ikarian Capital first reported a position in BCLI in Q1 2021 and held it in 15 quarters. The position peaked at $1.16M in Q4 2021. 32 funds tracked by Wall St. Rank hold BCLI as of Q1 2025.

  • Ikarian Capital reported no remaining BRAINSTORM CELL THERAPUTC position as of Q1 2025 after selling out during the quarter.
  • Ikarian Capital sold 6,016 BRAINSTORM CELL THERAPUTC shares in Q1 2025, an estimated $13.7K.
  • Ikarian Capital first reported a position in BRAINSTORM CELL THERAPUTC in Q1 2021 and held it in 15 quarters.
  • Ikarian Capital's BRAINSTORM CELL THERAPUTC position peaked at $1.16M in Q4 2021.
  • 32 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q1 2025.

Based on Ikarian Capital's 13F filing for Q1 2025, filed 15 May 2025.